The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical characteristics of patients with advanced hepatocellular carcinoma who received long-term treatment with atezolizumab and bevacizumab for more than one year.
 
Youngun Kim
No Relationships to Disclose
 
Beodeul Kang
No Relationships to Disclose
 
Jung Sun Kim
No Relationships to Disclose
 
Il-Hwan Kim
No Relationships to Disclose
 
Hyeyeong Kim
No Relationships to Disclose
 
Won Suk Lee
No Relationships to Disclose
 
Yun Beom Sang
No Relationships to Disclose
 
Sanghoon Jung
No Relationships to Disclose
 
Chan Kim
Honoraria - Bristol-Myers Squibb; MSD; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Oncocross; ONEGENE BIOTECHNOLOGY; Ono Pharmaceutical; Panolos Bioscience
Research Funding - Boryung; CHA vaccine institute; Dong-A ST; Oncocross; Roche; Samyang; Virocure
 
Hong Jae Chon
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Celgene Cancer Care Links/BMS; Eisai; Green Cross; Menarini; MSD Oncology; Ono Pharmaceutical; Roche; Sanofi; SERVIER; Sillajen
Speakers' Bureau - Bayer; BMS; Celgene/Bristol-Myers Squibb; Dong-A ST; Eisai; Menarini; Roche; Sanofi; SERVIER
Research Funding - Boryung (Inst); Dong-A ST (Inst); Roche (Inst)